Innovative Extended-Release
Innovative Extended-Release
SKP2 Inhibitor Tablet
SKP2 Inhibitor Tablet
Embedded Files
Our SKP2 inhibitor tablet is specifically designed for the treatment of psoriasis. This innovative extended-release formulation ensures the gradual release of the active ingredient in the gastrointestinal tract, providing sustained therapeutic effects.
Reasons For Choosing Tablet Formulation
Reasons For Choosing Tablet Formulation
Convenience and Compliance: Tablets are easy to administer, store, and carry out, making tablets one of the most convenient choices for patients.
Precise Dosage: Tablets allow for precise dosing, ensuring each tablet contains an exact amount of the active pharmaceutical ingredient (API).
Cost-effectiveness: Tabltes are cost-effective to manufacture on a large scale, making them an economically viable option for patients.
Controlled Release: The extended-release tablet formulation can provide a steady release of the SKP2 inhibitor, making a consistent therapeutic effect over a longer period.
The Role of Each Excipient
The Role of Each Excipient
Potential Challenges and Difficulties
Potential Challenges and Difficulties
Solubility Challenges
Solubility challenges are intrinsically linked to bioavailability. If a drug cannot dissolve adequately in the gastrointestinal tract, it cannot enter the bloodstream effectively, leading to low bioavailability.
Previous related calculations have shown that our compound has only moderate solubility, so ensuring sufficient solubility of the SKP2 inhibitor in the gastrointestinal tract to achieve the desired therapeutic effect is the first challenge.
Uniformity of API Distribution
Achieving uniform distribution of API throughout the tablet is essential for consistent dosing. Variability in the distribution can lead to dose variations, thereby impacting the drug's efficacy and safety.
Release Profile
Designing the extended-release formulation to achieve the desired release profile while maintaining the efficacy and safety of the drug is critical. The challenges we meet are how to develop a matrix or coating system that can precisely control the drug release rate and ensure the release profile is reproducible across different batches.
Page updated
Report abuse